Iambic has entered into a multi-year technology and drug discovery collaboration with Takeda to advance the AI-driven design of small molecule therapeutics across select high-priority programs.
The partnership will initially focus on Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas, leveraging Iambic’s artificial intelligence platforms alongside its integrated wet lab capabilities.
Under the agreement, Takeda will gain access to Iambic’s proprietary suite of AI drug discovery technologies, including NeuralPLexer, a model designed to predict protein–ligand complex structures. The platform is intended to accelerate drug discovery and development by improving candidate selection, increasing the probability of success, and shortening timelines from early discovery through investigational new drug (IND) readiness.
The collaboration combines Iambic’s AI-based computational models with its fully integrated, high-throughput, and automated wet lab infrastructure. These capabilities support a rapid Design–Make–Test–Analyze workflow aimed at accelerating the progression of discovery programs and optimizing small molecule development.
Financially, the agreement includes upfront payments, research funding, and technology access fees for Iambic. The company is also eligible to receive success-based milestone payments that could exceed $1.7 billion, along with royalties on net sales of any products developed through the collaboration.
Iambic is a clinical-stage life science and technology company focused on discovering and developing novel medicines using its AI-driven discovery and development platform. The collaboration further reflects Takeda’s strategy to integrate advanced artificial intelligence approaches into its research engine to accelerate the development of new medicines addressing unmet patient needs.
The partnership will be headquartered operationally across Iambic’s sites in San Diego and Cambridge, while supporting Takeda’s global research and development efforts.
Also Read